Lilly's Prevail walks away from gene editing collab with Precision

Nine months after Eli Lilly’s Prevail Therapeutics reduced the biobucks value of a gene editing deal with Precision Biosciences, the Big Pharma subsidiary has walked away from the partnership entirely.